Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.
BACKGROUND
Calcineurin inhibitors play an important role in chronic allograft dysfunction. Sirolimus is an interesting alternative in renal transplant patients because it is less nephrotoxic than calcineurin inhibitors.


METHODS
A chart review of the clinical outcome of kidney transplant patients converted to sirolimus with progressive allograft dysfunction is reported herein. Fifteen patients (average age: 32.3 years, 44 months mean time of conversion) were included. Indication for conversion was a >20% increase in serum creatinine over the last 6 months or progression to the range of 2-4.5 mg/dL. Patients underwent abrupt cessation of cyclosporine and sirolimus addition at 2-5 mg/day.


RESULTS
Concomitant immunosuppression remained unchanged during conversion. Targeted sirolimus level was 8-12 ng/mL. Serum creatinine dropped from pre-conversion level of 2.75 +/- 0.83 to 2.14 +/- 0.67 and 1.97 +/- 0.66 mg/dL at 3 and 6 months (p <0.05). There was a significant decrease in blood urea nitrogen, hemoglobin and serum calcium at 3 months post-conversion as well as serum calcium and potassium at 6 months post-conversion (p <0.05). There were no rejection episodes. Patient and graft survival was 100% with three infectious complications.


CONCLUSIONS
Monitored sirolimus conversion with sharp withdrawal of calcineurin inhibitor is an alternative for patients with deteriorating renal function and chronic allograft nephropathy.
Martínez-Mier
Gustavo
G
Department of Organ Transplantation, School of Medicine, Universidad Cristobal Colon, Veracruz, Mexico. gmtzmier@ver.megared.net.mx
Méndez-López
Marco Tulio
MT
Estrada-Oros
Jorge
J
Budar-Fernandez
Luis F
LF
Soto-González
Juan I
JI
Méndez-Machado
Gustavo F
GF
Viñas Dozal
Julio Cesar
JC
D000328:Adult; D065095:Calcineurin Inhibitors; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D016030:Kidney Transplantation; D008297:Male; D008991:Monitoring, Physiologic; D011188:Potassium / Q000097:blood; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014508:Urea / Q000097:blood
D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014508:Urea; D003404:Creatinine; D011188:Potassium; D002118:Calcium; D020123:Sirolimus